

Advances in Experimental Medicine and Biology 1166

Elisabetta Baldi
Monica Muratori *Editors*

Genetic Damage in Human Spermatozoa

Second Edition

 Springer

Advances in Experimental Medicine and Biology

Volume 1166

Editorial Board

IRUN R. COHEN, *The Weizmann Institute of Science,
Rehovot, IL, Israel*

ABEL LAJTHA, *N.S.Kline Institute for Psychiatric Research,
Orangeburg, NY, USA*

JOHN D. LAMBRIS, *University of Pennsylvania, Philadelphia, PA, USA*

RODOLFO PAOLETTI, *University of Milan, Milan, IT, Italy*

NIMA REZAEI, *Children's Medical Center Hospital,
Tehran University of Medical Sciences, Tehran, IR, Iran*

More information about this series at <http://www.springer.com/series/5584>

Elisabetta Baldi • Monica Muratori
Editors

Genetic Damage in Human Spermatozoa

Second Edition

 Springer

Editors

Elisabetta Baldi
Department of Clinical and
Experimental Medicine
University of Florence
Florence, Italy

Monica Muratori
Department of Experimental and
Clinical Biomedical Sciences “Mario
Serio”
University of Florence
Florence, Italy

ISSN 0065-2598

ISSN 2214-8019 (electronic)

Advances in Experimental Medicine and Biology

ISBN 978-3-030-21663-4

ISBN 978-3-030-21664-1 (eBook)

<https://doi.org/10.1007/978-3-030-21664-1>

© Springer Nature Switzerland AG 2014, 2019

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

This book is dedicated to Prof. Gianni Forti, who guided our activities with great sapience.

Preface

The goal of the male gamete is to deliver a fully intact and functioning paternal genome to the oocyte. To fulfill this aim, the process of chromatin maturation during spermiogenesis must be correctly completed to guarantee DNA protection during the long journey to reach the oocyte and to properly decondense and form the male pronucleus after fertilization. Genetic abnormalities in spermatozoa can be generated in any phase of the sperm production and life and may be due to endogenous and exogenous conditions, the latter including in vitro manipulation for assisted reproduction and gonadotoxic therapies. In addition, emerging studies point out the importance of the damage to the sperm epigenome and address the mechanisms involved in generating it. All these abnormalities may have profound consequences for male fertility status and even for the health of the progeny. This book presents an updated overview of the various types of damage that may affect sperm chromatin. Besides the main mechanisms involved in the generation of de novo mutations and DNA strand breaks and oxidation, two chapters of the book are dedicated to sperm epigenome and epigenetic damage and their consequences for the progeny. In addition, as one of the most important issues regards the possible medical interventions to reduce or prevent sperm DNA fragmentation, one chapter faces the important aspect of pharmacological and surgical treatments, lifestyle modifications, and prevention against exposure to environmental and occupational toxicants.

We wish to thank all the authors for their invaluable contributions to the book. They are all expert scientists in the field, and we appreciate their willingness to offer their knowledge in this important branch of reproductive medicine. We hope that this book will help the researchers in the topics of reproduction and serve as a reference for medical and technical staff working in assisted reproduction laboratories.

Florence, Italy

Elisabetta Baldi
Monica Muratori

Contents

1 Genetic Factors Affecting Sperm Chromatin Structure	1
Méline Blanco and Julie Cocquet	
2 Age-Dependent De Novo Mutations During Spermatogenesis and Their Consequences.	29
Francesca Cioppi, Elena Casamonti, and Csilla Krausz	
3 The Sperm Epigenome: Implications for Assisted Reproductive Technologies.	47
Douglas T. Carrell	
4 Epigenetic Transgenerational Inheritance	57
Joan Blanco Rodríguez and Cristina Camprubí Sánchez	
5 Sperm DNA Fragmentation: Mechanisms of Origin.	75
Monica Muratori, Sara Marchiani, Lara Tamburrino, and Elisabetta Baldi	
6 Sperm DNA Fragmentation: Consequences for Reproduction.	87
Luke Simon, Benjamin Emery, and Douglas T. Carrell	
7 Oxidative Damage to Sperm DNA: Attack and Defense	107
Joel R. Drevet and R. J. Aitken	
8 Interventions to Prevent Sperm DNA Damage Effects on Reproduction.	119
Sandro C. Esteves	
9 Cryopreservation of Sperm: Effects on Chromatin and Strategies to Prevent Them.	149
Donatella Paoli, Marianna Pelloni, Andrea Lenzi, and Francesco Lombardo	
10 Effect on Sperm DNA Quality Following Sperm Selection for ART: New Insights	169
Nicoletta Tarozzi, Marco Nadalini, and Andrea Borini	

11 Sperm DNA Damage in Cancer Patients 189

Hermance Beaud, Amelie R. Tremblay, Peter T. K. Chan,
and Geraldine Delbes

Index..... 205

Contributors

R. J. Aitken Priority Research Centre for Reproductive Science, Faculty of Science, University of Newcastle, Callaghan, NSW, Australia

Hunter Medical Research Institute, New Lambton Heights, NSW, Australia

Elisabetta Baldi Department of Experimental and Clinical Medicine, Unit of Sexual Medicine and Andrology, Center of Excellence DeNothe, University of Florence, Florence, Italy

Hermance Beaud Institut national de la recherche scientifique, Centre INRS – Institut Armand-Frappier, QC, Canada

Mélina Blanco INSERM, U1016, Institut Cochin, Paris, France
CNRS, UMR8104, Paris, France

Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France

Joan Blanco Rodríguez Genetics of Male Fertility Group, Unitat de Biologia Cel·lular (Facultat de Biociències), Universitat Autònoma de Barcelona, Bellaterra(Cerdanyola del Vallès), Spain

Andrea Borini 9.baby Family and Fertility Center, Bologna, Italy

Cristina Camprubí Sánchez GenIntegral, Barcelona, Spain

Reference Laboratory Genetics, L'Hospitalet de Llobregat, Spain

Unitat de Biologia Cel·lular i Genètica Mèdica (Facultat de Medicina), Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain

Douglas T. Carrell Andrology and IVF Laboratories, Department of Surgery, and Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, UT, USA

Elena Casamonti Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Florence, Florence, Italy

Peter T. K. Chan Division of Urology, McGill University Health Center, QC, Canada

Francesca Cioppi Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Florence, Florence, Italy

Julie Cocquet INSERM, U1016, Institut Cochin, Paris, France

CNRS, UMR8104, Paris, France

Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France

Geraldine Delbes Institut national de la recherche scientifique, Centre INRS – Institut Armand-Frappier, QC, Canada

Joel R. Drevet GReD Laboratory, CNRS UMR6293 – INSERM U1103 – Université Clermont Auvergne, Faculté de Médecine, Clermont-Ferrand, France

Benjamin Emery Department of Surgery (Urology), University of Utah School of Medicine, Salt Lake City, UT, USA

Sandro C. Esteves ANDROFERT, Andrology and Human Reproduction Clinic, Referral Center for Male Reproduction, Campinas, SP, Brazil

Department of Surgery (Division of Urology), University of Campinas (UNICAMP), Campinas, SP, Brazil

Faculty of Health, Aarhus University, Aarhus, Denmark

Csilla Krausz Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Florence, Florence, Italy

Andrea Lenzi Laboratory of Seminology – Sperm Bank “Loredana Gandini”, Department of Experimental Medicine, University of Rome “La Sapienza”, Rome, Italy

Francesco Lombardo Laboratory of Seminology – Sperm Bank “Loredana Gandini”, Department of Experimental Medicine, University of Rome “La Sapienza”, Rome, Italy

Sara Marchiani Department of Experimental and Clinical Medicine, Unit of Sexual Medicine and Andrology, Center of Excellence DeNothe, University of Florence, Florence, Italy

Monica Muratori Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, Unit of Sexual Medicine and Andrology, Center of Excellence DeNothe, University of Florence, Florence, Italy

Marco Nadalini 9.baby Family and Fertility Center, Bologna, Italy

Donatella Paoli Laboratory of Seminology – Sperm Bank “Loredana Gandini”, Department of Experimental Medicine, University of Rome “La Sapienza”, Rome, Italy

Marianna Pelloni Laboratory of Seminology – Sperm Bank “Loredana Gandini”, Department of Experimental Medicine, University of Rome “La Sapienza”, Rome, Italy

Luke Simon Department of Surgery (Urology), University of Utah School of Medicine, Salt Lake City, UT, USA

Lara Tamburrino Department of Experimental and Clinical Medicine, Unit of Sexual Medicine and Andrology, Center of Excellence DeNothe, University of Florence, Florence, Italy

Nicoletta Tarozzi 9.baby Family and Fertility Center, Bologna, Italy

Amelie R. Tremblay Institut national de la recherche scientifique, Centre INRS – Institut Armand-Frappier, QC, Canada



Genetic Factors Affecting Sperm Chromatin Structure

1

Mélina Blanco and Julie Cocquet

Abstract

Spermatozoa genome has unique features that make it a fascinating field of investigation: first, because, with oocyte genome, it can be transmitted generation after generation; second, because of genetic shuffling during meiosis, each spermatozoon is virtually unique in terms of genetic content, with consequences for species evolution; and finally, because its chromatin organization is very different from that of somatic cells or oocytes, as it is not based on nucleosomes but on nucleoprotamines which confer a higher order of packaging. Histone-to-protamine transition involves many actors, such as regulators of spermatid gene expression, components of the nuclear envelop, histone-modifying enzymes and readers, chaperones, histone variants, transition proteins, protamines, and certainly many more to be discovered.

In this book chapter, we will present what is currently known about sperm chromatin structure and how it is established during spermiogenesis, with the aim to list the genetic factors that regulate its organization.

Keywords

Spermatozoa · Chromatin · Protamine · Nucleosome · Histone · Gene expression · Nucleus · Spermatids · Spermiogenesis

Introduction

Spermatozoa are produced through a multi-step process called spermatogenesis, during which spermatogonial stem cells at the base of the seminiferous tubules enter the differentiation pathway to ultimately give rise to spermatozoa, released in the lumen of the testicular seminiferous tubules. Spermatogenesis can be divided into three phases: mitotic phase, meiosis, and post-meiotic phase or spermiogenesis. During mitotic phase, spermatogonial stem cells undergo mitotic divisions to maintain the spermatogonial stem cell pool; some of them differentiate into primary spermatocytes. Each primary spermatocyte undergoes DNA replication and meiotic division to produce four haploid round spermatids. Round spermatids then differentiate into elongated spermatids in a process that involves dramatic morphological changes including cytoplasm removal, acrosome biogenesis, development of flagellum for motility, accumulation of mitochondria in the midpiece, and extensive chromatin remodeling that results in nuclear condensation and transcriptional silencing (Russell et al. 1990). The

M. Blanco · J. Cocquet (✉)
INSERM, U1016, Institut Cochin, Paris, France
CNRS, UMR8104, Paris, France
Université Paris Descartes, Sorbonne Paris Cité,
Faculté de Médecine, Paris, France
e-mail: julie.cocquet@inserm.fr

post-meiotic differentiation of round spermatids into spermatozoa is called spermiogenesis. During this step, spermatid chromatin is extensively modified and remodeled to give rise to a chromatin organization only found in spermatozoa. Indeed, in all other cells (somatic cells, female germ cells, and male germ cells until spermatid stage), the nucleosome is the core particle of chromatin structure (Luger et al. 1997). Histone proteins H2A, H2B, H3, and H4 assemble into an octamer around which 146 base pairs of DNA are wrapped, and this nucleosome structure occurs every 200 base pairs in the eukaryotic genome (McGhee and Felsenfeld 1980; Luger et al. 1997). In sperm chromatin, the basal unit is not the nucleosome but the nucleoprotamine, formed of smaller, more basic proteins (richer in arginine) than histones: the protamines. Sperm chromatin is organized as toroids containing ~50–100kb of DNA, leading to a chromatin structure 5–10 times more condensed than nucleosome-based chromatin (Ward and Coffey 1991; Balhorn 2007). This tight compaction is essential to allow DNA to fit into a nucleus that is seven times smaller than an interphasic somatic cell nucleus (Ward and Coffey 1991) and to protect the paternal genome from physical and chemical damages. It is also possible that a small nucleus is a hydrodynamic advantage that confers a higher speed to spermatozoa during their transit (Braun 2001).

Briefly, the process of replacement of histones by protamines requires (i) opening of the histone-based chromatin structure facilitated by histone posttranslational modifications (PTM) – in particular histone hyperacetylation – and incorporation of histone variants, (ii) binding of bromodomain proteins to acetyl residues and recruitment of chromatin-remodeling proteins and of transition proteins, (iii) formation and repair of DNA breaks, and (iv) incorporation of protamines leading to a protamine-based compact chromatin structure. At the end of this process, most histones have been replaced by protamines. A small portion of histones (~1% in mice, ~10% in humans) is retained in the spermatozoa genome and contributes to the epigenetic program of the embryo (Balhorn et al. 1977;

Gatewood et al. 1990; Hammoud et al. 2009; Brykczynska et al. 2010; Erkek et al. 2013; Ihara et al. 2014; Carone et al. 2014; Samans et al. 2014; Royo et al. 2016; Yoshida et al. 2018; Yamaguchi et al. 2018). [For review, see Champroux et al. (2018).]

Studying animal models (mostly knockout mice) and patient cases, researchers and clinicians have found many genes involved in histone-to-protamine transition, and many more will certainly be discovered. Each of them is a genetic factor which could alter chromatin structure when mutated. In this review, we will present their known or predicted roles while describing the key steps leading to the transition from a histone-based chromatin to protamine-based chromatin (see also Table 1.1).

Regulation of Spermatid Gene Expression

The differentiation of round spermatids into spermatozoa involves profound morphological and functional changes and requires a very specific genetic program with thousands of genes only expressed at that time and regulated at the transcriptional and post-transcriptional levels (Steger 1999; White-Cooper and Davidson 2011; Kleene 2013). Studies of gene expression dynamic throughout spermatogenesis have shown that this program starts as early as the pachytene phase of meiosis [see, for instance, da Cruz et al. (2016) and Chen et al. (2018)].

Among the genes of which expression is activated/upregulated during spermiogenesis are those required for histone-to-protamine transition such as histone variants, chaperones, histone-modifying enzymes, transition proteins, and, of course, protamines themselves. Hence, transcription regulators which control the spermatid gene expression program can indirectly impact on sperm chromatin structure via deregulating key genes of this process.

This is particularly true for regulators of *Protamine 1* (*Prm1*) and *Protamine 2* (*Prm2*) gene expression: in the mouse, *Prm1* and *Prm2* are transcribed into mRNAs that can be detected

Table 1.1 List of genes of which mutations have been shown to result in abnormal sperm chromatin structure

Gene name	Protein	Molecular role in spermiogenesis	Phenotype when mutated	Evidence of role in sperm chromatin structure	References
Genes encoding chromatin proteins					
<i>Prrm1/2</i>	<i>Protamine 1/2</i>	DNA compaction in male germ cells	<i>Prrm1</i> ^{+/-} and <i>Prrm2</i> ^{+/-} chimeric male mice are infertile with abnormal chromatin compaction and sperm DNA damage. Another study found that <i>Prrm2</i> ^{+/-} males are fertile and that <i>Prrm2</i> ^{-/-} males are infertile with chromatin compaction defect.	Acridin orange assay on <i>Prrm1</i> ^{+/-} and <i>Prrm2</i> ^{+/-} chimeric mice and Comet assay on <i>Prrm2</i> ^{+/-} chimeric mice sperm. Electron microscopy on sperm from <i>Prrm2</i> ^{+/-} chimeric mice and <i>Prrm2</i> ^{-/-} mice.	Cho et al. (2001, 2003); Schneider et al. (2016)
<i>Tnp1/2</i>	<i>Transition protein 1/2</i>	Intermediates in histone-to-protamine transition	<i>Tnp1</i> ^{-/-} and <i>Tnp2</i> ^{-/-} mice are hypofertile but present chromatin compaction defect and high level of unprocessed PRM2-precursor in sperm. <i>Tnp1</i> ^{-/-} <i>Tnp2</i> ^{-/-} double knockout mice are infertile with chromatin compaction defect and unprocessed PRM2 precursor protein.	Electron microscopy and western blot on spermatids at different stages.	Yu et al. (2000); Zhao et al. (2001); Zhao et al. (2004)
<i>H1fnt (H1f2)</i>	<i>Testis-specific histone H1</i>	Testis specific Histone H1	Knockout male mice are infertile with sperm chromatin compaction defect, nuclear abnormalities in spermatids, and low protamine level in sperm.	Quantification of propidium iodide in sperm DNA by FACS, western blot on sperm and electron microscopy on elongated spermatids.	Tanaka et al. (2005); Martianov et al. (2005)
<i>Th2a (Hist1h2aa) and Th2b (Hist1h2ba)</i>	<i>TH2A (histone cluster 1 H2A family member a, Hist1h2aa) and TH2B (histone H2B type 1-A, Hist1h2ba)</i>	Testis specific Histone 2 variants	In <i>Th2b</i> ^{-/-} mouse, fertility is not altered. The absence of TH2B is compensated by the overexpression of H2B in testes. However, transgenic mice, in which TH2B is fused to a C-terminal tag, are infertile, and elongating spermatids fail to differentiate and to compact their chromatin. TH2B is incorporated into chromatin but is not replaced by transition proteins or protamines in elongating spermatids. In <i>Th2a</i> ^{-/-} <i>Th2b</i> ^{-/-} double mutant mice, TNPs and PRMs also fail to incorporate into chromatin, and H2B is overexpressed.	Electron microscopy on sperm, MNase digestion in condensed spermatids, and immunostaining of spermatids at different stages. Histone liquid chromatography and mass spectrometry.	Montellier et al. (2013); Shinagawa et al. (2015)

(continued)